Novo Nordisk A/S $NVO Stock Sold by Quadrant Capital Group LLC

Quadrant Capital Group LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 44.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,869 shares of the company’s stock after selling 51,643 shares during the quarter. Quadrant Capital Group LLC’s holdings in Novo Nordisk A/S were worth $2,431,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S in the 1st quarter worth about $287,660,000. State Street Corp lifted its holdings in shares of Novo Nordisk A/S by 0.6% during the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after buying an additional 32,641 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after buying an additional 71,684 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Novo Nordisk A/S by 3.2% during the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock valued at $166,396,000 after buying an additional 141,376 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock valued at $124,844,000 after buying an additional 213,443 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced an average 25% reduction in body weight after 68 weeks among women with obesity or overweight in a late-stage analysis. The result strengthens the drug’s potential as a successor to Wegovy and could improve Novo’s long-term position in the expanding obesity-treatment market. Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis
• Positive Sentiment: The CagriSema data prompted a recent rally as investors viewed the treatment’s efficacy as a potential catalyst for renewed growth. Regulatory submissions and further clinical progress could provide additional upside, although approval is not yet guaranteed. Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
• Positive Sentiment: Novo expanded its 2026 share buyback, increasing its treasury-share stake to 1.2%. The program signals management’s confidence and may support earnings per share by reducing the number of shares outstanding. Novo Nordisk expands 2026 share buyback
• Neutral Sentiment: Novo remains a major player in diabetes and obesity treatments, with additional pipeline projects and partnerships offering potential growth over the next decade. However, those benefits depend on successful trials, regulatory approvals, manufacturing investment, and commercialization. Where Will Novo Stock Be in 10 Years?
• Negative Sentiment: Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates. These concerns help explain why the stock remains under pressure despite the promising CagriSema results. How Investors May Respond To Novo Nordisk Obesity Drug Competition

Novo Nordisk A/S Trading Down 0.6%

Novo Nordisk A/S stock opened at $39.10 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The company has a market capitalization of $174.58 billion, a price-to-earnings ratio of 9.56, a PEG ratio of 1.34 and a beta of 0.76. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company’s fifty day moving average price is $42.21 and its two-hundred day moving average price is $44.01.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The company had revenue of $11.98 billion for the quarter. On average, analysts forecast that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This represents a dividend yield of 258.0%. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NVO shares. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Barclays reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 7th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Friday, October 9th. UBS Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, DZ Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $59.44.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.